Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative Panitumumab and mFOLFOX-6 in Quadruple Wild-Type Rectal Cancer
NCT03000374Phase 2Completed
- Sponsor
- GEMCAD
- Start
- May 2017
- Primary completion
- Oct 2020
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of panitumumab in rectal cancer, sponsored by GEMCAD. Primary endpoint: Pathologic complete response. Started May 2017; status: completed.
02
Drugs
panitumumab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT03000374.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03000374.